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Abstract  28 
Anti-Aspergillus IgG antibodies are important biomarkers for the diagnosis of chronic 29 
pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA). We 30 
compared the performance of a new commercial EIA (Bordier Affinity Products) with those 31 
of the Bio-Rad and Virion\Serion EIAs. This assay is novel in the association of two 32 
recombinant antigens with somatic and metabolic antigens of A. fumigatus. In a prospective 33 
multicentre study, 436 serum samples from 147 patients diagnosed with CPA (136 sera/104 34 
patients) or ABPA (94 sera/43 patients) and from 205 controls (206 sera) were tested. We 35 
obtained sensitivities of 97%, 91.7%, and 86.1%, and specificities of 90.3%, 91.3%, and 36 
81.5% for the Bordier, Bio-Rad and Virion\Serion tests, respectively. The Bordier kit was 37 
more sensitive than the Bio-Rad kit (p<0.01), which was itself more sensitive than the 38 
Virion\Serion kit (p=0.04). The Bordier and Bio-Rad kits had similar specificities (p=0.8), 39 
both higher than that of the Virion\Serion kit (p=0.02). The areas under the ROC curves 40 
confirmed the superiority of the Bordier kit over the Bio-Rad and the Virion\Serion kits 41 
(0.977, 0.951 and 0.897, respectively; p<0.01 for each comparison). In a subset analysis of 42 
279 sera tested with the Bordier and Bio-Rad kits and an in-house immunoprecipitin assay 43 
(IPD), the Bordier kit had the highest sensitivity (97.7%), but the IPD tended to be more 44 
specific (71.2 and 84.7%, respectively; p=0.10).  45 
The use of recombinant, somatic and metabolic antigens in a single EIA improved the balance 46 
between sensitivity and specificity, resulting in an assay highly suitable for use in the 47 
diagnosis of chronic and allergic aspergillosis. 48 
  49 
4 
 
Introduction 50 
A. fumigatus is the species most frequently implicated in pulmonary aspergillosis (1, 2). 51 
Chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis (ABPA) 52 
occur in immunocompetent hosts (3–9). CPA usually affects patients with underlying lung 53 
disease, such as mycobacterial infections, chronic obstructive pulmonary disease (COPD), 54 
ABPA and emphysema (7, 9, 10). It has been estimated that over 4.8 million asthmatic 55 
patients worldwide suffer from ABPA and that about 240,000 people in Europe have CPA 56 
(11). Patients suffering from asthma or cystic fibrosis (CF) may become sensitized to 57 
Aspergillus antigens, resulting in ABPA, Aspergillus-related bronchitis or severe asthma (1, 58 
12). 59 
 60 
The diagnosis of CPA and ABPA remains challenging and is based on a combination of 61 
clinical, radiological, biological and mycological criteria (8, 13, 14). The detection of anti-62 
Aspergillus antibodies is considered to be an important criterion (1, 2, 6, 7, 12, 14–16). 63 
Several serological methods are available and those based on immunoprecipitin detection 64 
(IPD) are used for confirmation purposes, due to their high specificity(16) However, they 65 
have not been standardized and are not easy to perform. Thus, screening tests to detect anti-66 
Aspergillus IgG by indirect hemagglutination, indirect immunofluorescence or enzyme 67 
immunoassay (EIA; also called enzyme-linked immunosorbent assay or ELISA), are often 68 
preferred (16–18). The use of EIAs also facilitates quantitative evaluation of the antibody 69 
response and automation, leading to rapid and easy routine selection (16–18). 70 
 71 
We conducted a prospective multicentre study to evaluate the performance of a new 72 
commercial anti-Aspergillus IgG kit, the Aspergillus fumigatus IgG ELISA kit (Bordier 73 
Affinity Products). This assay is novel in terms of its antigen composition, because it 74 
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combines two recombinant antigens with somatic and metabolic antigens from A. fumigatus. 75 
We compared this assay with two other commercial EIAs — the Platelia Aspergillus IgG 76 
(Bio-Rad), and the ELISA Classic Aspergillus IgG (Virion\Serion) — and an in-house IPD 77 
method (19).  78 
 79 
Materials and Methods 80 
Study design, patients and sera 81 
This prospective study was conducted in the five French university hospitals of Grenoble, 82 
Rennes, Lyon, Dijon, and Besançon. Immunocompetent patients with suspected non-invasive 83 
aspergillosis were included between January 2013 and April 2015. Patients were assigned to 84 
one of six groups on the basis of clinical, radiological and biological criteria, in accordance 85 
with the classifications established by the international committees of experts available at the 86 
time of the study (Table 1) (6–8, 13, 20). Cystic fibrosis (CF) patients were excluded from the 87 
group of colonised patients (group 2), because their Aspergillus IgG levels have been reported 88 
to be high even in the absence of ABPA, and persistent colonisation may itself induce IgG 89 
responses in these patients (12, 21–23). CPA patients were assigned to groups 3, 4 or 5 and 90 
group 6 included patients with ABPA. Immunocompromised patients at risk of invasive 91 
aspergillosis were excluded. 92 
 93 
Laboratory methods 94 
All serum samples were stored at -20°C until processing. Each was tested at each centre with 95 
the three EIAs: Platelia Aspergillus IgG (Bio-Rad, Marnes-la-Coquette, France), ELISA 96 
Classic Aspergillus fumigatus IgG (Virion\Serion, Würzburg, Germany) and ELISA 97 
Aspergillus fumigatus IgG (Bordier Affinity Products, Crissier, Switzerland), according to the 98 
manufacturers' recommendations. If the result of at least one test was positive or equivocal, 99 
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the serum sample was subjected to testing with an in-house IPD method (19). Testing by this 100 
last method was centralized at Grenoble University Hospital, to ensure standardisation. 101 
 102 
Platelia Aspergillus IgG (Bio-Rad). This assay relies on one recombinant antigen that is 103 
coated on the ELISA microplate. Values ≥10 AU/ml were considered positive, values of 5-10 104 
AU/ml were classified as equivocal and values <5 AU/ml were considered negative. Samples 105 
yielding >80 AU/ml were diluted and retested.  106 
 107 
ELISA Classic Aspergillus fumigatus IgG (Virion\Serion). The antigenic composition of this 108 
assay is not available from the manufacturer. The OD measured was converted into 109 
concentration in AU/ml by reference to the standard curve equation provided in each batch. 110 
Values ≥70 AU/ml were considered positive, values of 50-70 AU/ml were classified as 111 
equivocal and values <50 AU/ml were considered negative. 112 
 113 
ELISA Aspergillus fumigatus IgG (Bordier Affinity Products).The wells were coated with the 114 
two recombinant antigens, dipeptidyl peptidase type V (chymotrypsin) and ribonuclease 115 
(mitogillin), and the somatic and metabolic antigens (24). An OD index was calculated  by 116 
OD of the sample / OD of a cut off provided in the kit. OD index values ≥1 were considered 117 
positive, values of 0.8-1 were considered equivocal, and values <0.8 were considered 118 
negative.  119 
 120 
Immunoprecipitin detection. We used a double-diffusion gel-electrophoresis technique with 121 
in-house metabolic and somatic antigens different from those used in the Bordier EIA (19). 122 
Briefly, we dispensed 10µl of antigen solution into the agarose wells (1%) (Agarose NA, 123 
Amersham Biosciences). After migration, we added 200µl of serum to the troughs. After 124 
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incubation, catalase activity was detected by adding 20% hydrogen peroxide. The precipitin 125 
bands were stained with Amidoschwarz (Merck, USA). The result of the test was considered 126 
positive if ≥2 precipitin bands were detected and equivocal if only one precipitin band was 127 
detected (19). If catalase activity was detected, the result was considered positive regardless 128 
of the number of precipitin bands (25). 129 
 130 
Statistical analysis 131 
The baseline characteristics of the groups of patients were compared in Fisher’s exact tests 132 
and Wilcoxon tests for qualitative and quantitative variables, respectively. We used the 133 
Cochran Q test followed by McNemar post-hoc tests with Holm correction for multiple 134 
comparisons to compare the sensitivities and specificities of the assays. We calculated that a 135 
sample size of 223 serum samples from patients and 192 from controls would be sufficient to 136 
detect a significant difference with a power of 0.9. We calculated the Youden’s index 137 
(sensitivity+specificity–1) and the diagnostic odds ratio (DOR) as previously described (26).  138 
We carried out two secondary analyses. One after the exclusion of patients diagnosed solely 139 
on the basis of the presence of anti-Aspergillus-specific IgG and/or precipitins, to prevent 140 
overestimation and the other after the exclusion of the sera showing equivocal results. The 141 
EIAs were compared by calculating the area under the ROC curve (ROC AUC). The inter-142 
assay reproducibility (coefficient of variation (CV) and standard deviation (SD)) of the 143 
Bordier test was evaluated on the basis of 39 measurement on the same sample, as an internal 144 
quality control. A p value <0.05 was considered significant. Statistical analyses were 145 
performed with SAS 9.3 (SAS Institute Inc., Cary, NC, USA).  146 
 147 
Results 148 
Patients and sera 149 
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We included 352 patients in total. They had a median age of 58.9 years [47.0-71.5], 5% were 150 
minors (age<18), and 55% were male. Serum samples were collected at the university 151 
hospitals of Grenoble, Rennes, Lyon, Dijon, and Besançon (n= 239, 74, 70, 31 and 22, 152 
respectively).  The commonest underlying lung conditions in the controls and patients are 153 
shown in Table 2. The distributions of the 352 patients and the 436 sera are detailed in Tables 154 
1 and 3.  155 
 156 
Test performances 157 
The performances of the three EIAs when equivocal results were treated as positive are shown 158 
in Table 3A. Overall, the sensitivity of the Bordier assay (97%) was significantly higher than 159 
that of the Bio-Rad assay (91.7%),which was itself higher than that of the Virion\Serion assay 160 
(86.1%) (McNemar p<0.05). The specificities of the Bordier and Bio-Rad tests were similar 161 
(90.3% and 91.3%, respectively; McNemar p=0.8) but significantly higher than that of the 162 
Virion\Serion assay (81.5%; McNemar p=0.02 for both comparison). According to Youden’s 163 
index, the Bordier assay provided the best balance between sensitivity and specificity. Bordier 164 
showed the best DOR and Bio-Rad had a greater DOR than Serion. The 95% confidence 165 
intervals (CIs) confirm that Bio-Rad and Bordier are more discriminatory than Serion. These  166 
results were confirmed by the area under the ROC curve (AUC) analysis, which showed that 167 
the performances of the Bordier and Bio-Rad assays were excellent, with AUCs exceeding 168 
0.9. The AUC of the Bordier assay (0.977; 95%CI [0.962; 0.991]) was even greater than those 169 
of the Bio-Rad and Virion\Serion assays (0.951 [0.928; 0.974] and 0.897 [0.863; 0.931]) 170 
respectively) (p<0.01) (Figure 2). 171 
Based on these results, we decided to compare the performances of the best two EIAs 172 
(Bordier and Bio-Rad) with that of the IPD assay, for the 279 sera for which one of the three 173 
EIAs gave a positive or equivocal result and for which a sufficiently large volume of the 174 
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sample remained for additional testing. The Bordier assay was again found to be the most 175 
sensitive (McNemar p<0.05) (Table 3B). The Bio-Rad assay was more sensitive than the IPD 176 
assay only if equivocal results were considered to be negative (McNemar p=0.049; data not 177 
shown).The IPD tended to be more specific than the Bordier assay (84.7% and 71.2 % 178 
respectively; p=0.10). Youden’s index favoured the IPD assay but Bordier had the better 179 
DOR compared to Bio-Rad and IPD.  180 
In a secondary analysis performed after the exclusion of the 20 patients diagnosed solely on 181 
the basis of the presence of anti-Aspergillus antibodies, the comparisons of the three EIAs and 182 
of the AUCs were unchanged and the same differences were observed (p<0.01 for the 183 
Cochran Q test and p< 0.05 for the McNemar tests in all the comparisons). In the comparison 184 
of the IPD assay with the best two EIAs, we observed a difference in the results obtained from 185 
the pattern described above. The sensitivity of the Bordier assay tended to be higher than that 186 
of the Bio-Rad one, however the difference did not reached statistical significance (98% and 187 
94.5%, respectively; McNemar p=0.06) but both were more sensitive than the IPD assay 188 
(88%; McNemar p<0.01 and p=0.01, respectively). 189 
An analysis after exclusion of the equivocal results showed the same trend in the differences 190 
between the three EIAs. The sensitivity of Bordier (96.1%) tended to be higher than the one 191 
of Bio-Rad (91.7%) (McNemar p=0.07) and was significantly superior to the one of 192 
Virion\Serion (85.6%) (McNemar p<0.01). The specificity of the Bordier and the Bio-Rad 193 
assays were comparable (94.4% and 95.5 %, respectively; McNemar p=0.68) and tended to be 194 
higher than that of Virion\Serion (88.2 %; McNemar p=0.06).  195 
An analysis of test performances by patient category, and after correction for multiple 196 
comparisons, indicated that the new Bordier EIA was more sensitive than the Bio-Rad, 197 
Virion\Serion and IPD tests for group 5 of the CNPA with a sensitivity at 100% (Table 3A, 198 
3B and Figure2). In the other groups of patients, the only differences between sensitivities 199 
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remaining significant after correction for multiple comparisons were those for group 4, with 200 
the Bordier assay being more sensitive than the Virion\Serion and IPD assays (McNemar 201 
p<0.01 and p=0.01, respectively). The per-group analysis of group 1 revealed similar 202 
specificity results as for the total control group. The sample size for group 2 was insufficiently 203 
large for a separate analysis.   204 
The inter-assay CV of the Bordier EIA was 20% (SD=0.366). Quantitative results of the 205 
assays are detailed in Figure 2. Bordier EIA provided significantly fewer equivocal results 206 
(2.8%) than the Bio-Rad (6.7%), and the Virion\Serion (10.1%) (p<0.01 for each comparison 207 
with Bordier).  208 
 209 
Discussion 210 
We show here that the new commercially available Bordier EIA for the detection of anti-211 
Aspergillus IgG antibodies is suitable for the diagnosis of CPA and ABPA in 212 
immunocompetent patients. In this large prospective multicentre cohort of 352 patients 213 
providing 436 sera, this assay had a high sensitivity (97%) and specificity (90.3%) and its 214 
AUC value of 0.977 was excellent. This new assay was more sensitive than the other two 215 
EIAs used in routine clinical practice and the IPD assay used for confirmation. The sensitivity 216 
of the Bordier assay was remarkably high, at 100%, in the group of patients with chronic 217 
necrotizing pulmonary aspergillosis. Its specificity was similar to that of the Bio-Rad assay 218 
and higher than that of the Virion\Serion assay, but tended to be lower than that of the IPD 219 
assay. Overall, the best Youden’s index (indicating the trade-off between sensitivity and 220 
specificity) and the best DOR (indicating the discriminatory power) were obtained with the 221 
Bordier assay.   222 
The Bio-Rad and Virion\Serion EIAs have already been compared in a large retrospective 223 
study (17). The sensitivity and specificity obtained were 93.8% and 87.3% respectively, for 224 
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the Bio-Rad assay and 90.6% and 75.7%, respectively, for the Virion\Serion assay. Our 225 
findings confirm the superiority of the Bio-Rad assay over the Virion\Serion assay. Another 226 
recent study compared two EIAs, including the Bio-Rad EIA, and an IPD method based on 227 
commercial antigens in a prospective cohort (18). Again, the Bio-Rad assay had high 228 
sensitivity (93%), but its reproducibility was low, with an inter-assay CV of 33% which, 229 
according to the authors, precludes its use for the monitoring of patients. Another drawback of 230 
this test is the need to dilute and retest all samples yielding values greater than 80 AU/ml. 231 
Furthermore, one recent study evaluated a commercial western blot kit for the detection of 232 
anti-Aspergillus IgG (27). The authors reported a sensitivity of 90.0%-93.8% in CPA and 233 
ABPA patients, the specificity (94%) being estimated solely on the basis of the results for 234 
healthy blood donors as controls. Further studies are required to compare the EIAs and 235 
western-blot assay for the detection of anti-Aspergillus IgG.  236 
We found that the new Bordier EIA outperformed the Bio-Rad and Virion\Serion 237 
EIAs. This better performance may be explained by the association of two selected 238 
recombinant proteins with metabolic and somatic custom produced antigens. The chosen 239 
recombinants yielded the best performances in tests carried out with eight proteins and the 240 
purified galactomannan antigen (24). Preliminary results obtained through separate analyses 241 
of the two set of antigens, recombinant versus the metabolic/somatic custom-produced, 242 
suggested that the combination of these antigens was beneficial in terms of both sensitivity 243 
and specificity (data not shown). The gain in sensitivity and the parallel loss of specificity are 244 
counterbalanced by the use of the metabolic and somatic antigens of A. fumigatus included in 245 
this kit. This could also explain the greater discrimination of the Bordier test, which provided 246 
less equivocal results than the other tests (Figure 2).  247 
Our study confirmed the high specificity (84.7%) of the IPD based on in-house 248 
antigens that we have been using for more than 20 years which was even greater (96.6%) 249 
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when equivocal results were treated as negative (19). However it  was not significantly higher 250 
than that of the Bordier assay or the Bio-Rad assay, probably due to the loss of statistical 251 
power in the smaller sample size. Our selection of serum samples giving positive or equivocal 252 
results with one of the three EIAs for the analysis of IPD assay may have resulted in a slight 253 
overestimation of the sensitivity.  254 
Our results suggest that the Bordier EIA is suitable for use as a screening test in a two-255 
step strategy for the detection of anti-Aspergillus antibodies. Our findings confirm that the 256 
IPD assay is an appropriate specific method for precipitin detection and confirmation of the 257 
EIA results. In this case, equivocal results in the IPD assay should be considered negative, to 258 
increase specificity. If a one-step strategy is preferred, our results suggest that the Bordier 259 
EIA would be the best choice, as it gave the best compromise between sensitivity and 260 
specificity (Youden’s index = 0.873, Table 3A).  261 
The classification of colonised patients remains challenging. We decided to consider 262 
them as controls, as a diagnosis of infection had been ruled out in these patients. Conversely, 263 
Aspergillus spp. colonisation may be considered a prerequisite or initial stage of infection, 264 
accounting for the grouping together of colonised and infected patients in other 265 
studies(27).We also performed an analysis in which colonised individuals were grouped with 266 
the patients. The only modification to the results concerned the relative specificities of the 267 
Bordier, Bio-Rad and IPD assays which became comparable when equivocal results were 268 
considered negative (data not shown). 269 
 In conclusion, given its high Youden’s index and diagnostic odds ratio, indicating a 270 
good balance between sensitivity and specificity, this new Bordier EIA is suitable for the 271 
detection of anti-Aspergillus IgG for the diagnosis of chronic and allergic pulmonary 272 
aspergillosis. Further studies are required to confirm its use for monitoring clinical status in 273 
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patients. Finally, our results confirmed that immunoprecipitin detection was an appropriate 274 
method for confirming EIA results.  275 
  276 
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TABLE 1. Classification and distribution of the patients (adapted from (7, 8, 13, 20)). 393 
 394 
  Inclusion criteria 
Control 
groups  
(n=205) 
Group 1  
(n=191; 54.1%) 
 
Patients with respiratory symptoms in whom an Aspergillus-related disease had been ruled out 
      
Group 2  
Colonised patients 
(n=14; 4%) 
 
Patients with colonisation defined as the recovery of Aspergillus spp. from respiratory specimens at least twice within a period from 
10 days to one year and who did not match the criteria for CPA or ABPA diagnosis and had no major respiratory symptoms 
  Radiological criteria  Clinical manifestation   Aspergillus sp. evidence 
CPA 
(n= 104) 
Group 3 
simple aspergilloma 
(n=17; 4.8%) 
 
One “fungus ball": mass within a 
lung cavity surrounded by the "air 
crescent" on CT scan or X ray with 
no progression over ≥ 3 months 
 No alteration of the general 
condition and no haemoptysis 
 Aspergillus sp isolated from a respiratory sample 
AND/OR 
Histological evidence of Aspergillus sp hyphae 
AND/OR 
Positive anti-Aspergillus serum precipitins 
      
Group 4  
CCPA or CFPA 
(n=62; 17.6%) 
 
At least one cavitary lesion 
(CCPA) in the lung, with or 
without a “fungus ball", with 
progression over ≥ 3 months.  
CFPA = fibrotic destruction after 
CCPA 
 Alteration of the general condition 
(fever, weight loss, asthenia), 
chronic cough and/or haemoptysis 
progressing for ≥ 3 months 
 Aspergillus sp isolated from a respiratory sample 
AND/OR 
Histological evidence of Aspergillus sp hyphae 
AND/OR 
Positive anti-Aspergillus serum precipitins  
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Group 5  
CNPA 
(n=25; 7.1%) 
 
Expanding cavities, nodules, 
consolidations with progression 
over ≥ 1 month.  
 
 Mild immunodeficiency (diabetes, 
alcoholism, immunosuppressive 
drugs). Alteration of the general 
condition (fever, weight loss, 
asthenia), chronic cough and/or 
haemoptysis progression ≥ 1 month.  
 
 Aspergillus sp isolated from a respiratory sample 
AND/OR 
Histological evidence on a biopsy or surgical 
resection showing Aspergillus sp hyphae 
AND/OR 
Positive anti-Aspergillus serum precipitins and/or 
Aspergillus antigen detected in serum 
  Inclusion criteria 
ABPA 
(n=43) 
Group 6  
(n=43; 12.2%) 
 
Asthma or CF and  
the triad of alteration of respiratory function, presence of anti-Aspergillus specific IgE (>0.35 kAU/l) and high total serum IgE (> 
1000 IU/ml) (children: total IgE > twice the normal value for age) 
Or two of the following criteria: 
high eosinophil count >500 cells/µl, recent pulmonary lesions/worsening of existing lesions, serum precipitins or anti-Aspergillus 
IgG antibodies  
 395 
CPA. Chronic pulmonary aspergillosis 396 
CCPA. Chronic cavitary pulmonary aspergillosis 397 
CFPA. Chronic fibrosing pulmonary aspergillosis 398 
CNPA. Chronic necrotizing pulmonary aspergillosis 399 
ABPA. Allergic bronchopulmonary aspergillosis400 
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TABLE 2. Underlying lung conditions 401 
 402 
Previous pulmonary history Controls (n=167) 
Diseased patients 
(n=85) 
Allergic bronchopulmonary aspergillosis 0 (0) 25 (29.4)* 
Asthma 36 (21.6) 9 (10.6)ᶲ 
No previous respiratory history 30 (18) 1 (1.2) 
Cystic fibrosis 11 (6.6) 30 (35.3) 
Bronchiectasis 4 (2.4) 7 (8.2) 
Aspergillus sinusitis 1 (0.6) 0 (0) 
Previous pulmonary aspergillosis 1 (0.6) 15 (17.6) 
Previous Aspergillus colonisation 0 (0) 5 (5.9) 
Previous aspergilloma 0 (0) 9 (10.6) 
Emphysema 23 (13.8) 8 (9.4) 
Chronic obstructive pulmonary disease 45 (26.9) 19 (22.4) 
Respiratory deficiency 18 (10.8) 7 (8.2) 
Previous mycobacterial infection 12 (7.2) 9 (10.6) 
Assessment of respiratory symptoms† 20 (12) 2 (2.4) 
Previous cancer history 1 (0.6) 8 (9.4) 
Assessment before immunosuppresion£ 17 (10.2) 0 (0) 
Others¥ 16 (9.6) 6 (7.1) 
Missing previous pulmonary history: n=100 (38 controls and 62 diseased patients)  403 
Patients and controls may have more than one underlying condition. 404 
 405 
* 20 patients also had cystic fibrosis. 406 
ᶲ No patient had CF 407 
† Respiratory symptoms, such as shortness of breath, cough, wheezing rhonchi 408 
£ Including before treatment with biotherapy or before a transplantation (lung, heart, liver or kidney)  409 
¥Others: pneumothorax, asbestosis or solvent exposure, sarcoidosis, pulmonary hypertension, sleep 410 
apnoea, pulmonary embolism, previous haemoptysis. 411 
  412 
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TABLE 3:  413 
(A) Performances of three anti-Aspergillus IgG enzyme immunoassays for the diagnosis of chronic pulmonary aspergillosis and allergic 414
bronchopulmonary aspergillosis and  415 
(B) Performances of two anti-Aspergillus IgG enzyme immunoassays and the immunoprecipitation method 416 
Equivocal results were considered positive 417 
 418 
A    p-value* McNemar 
  
Bordier Bio-Rad Virion-Serion 
 
Bordier/ 
Bio-Rad 
Bordier/ 
Virion- 
Serion 
Bio-Rad/ 
Virion-
Serion 
Se % [95% CI] All sera n=230 97.0 [94.7 ; 99.2] 91.7 [88.2 ; 95.3] 86.1 [81.6 ; 90.1] <0.01 <0.01 <0.01 0.04 
 
Group 3 n=23 95.6 [78.0 ; 99.9] 95.6 [78.0 ; 99.9] 78.3 [56;3 ; 92.5] 0.02 NA 0.12 0.12 
 
Group 4 n=78 97.4 [91.0 ; 99.7] 92.3 [84.0 ; 97.1] 82.0 [71.7 ; 89.8] <0.01 0.12 <0.01 0.06 
 
Group 5 n=35 100 [90.0 ; 100] 91.4 [76.9 ; 98.2] 82.9 [66.3 ; 93.4] <0.01 NA NA 0.51 
 
Group 6 n=94 95.7 [89.4 ; 98.8] 90.4 [82.6 ; 95.5] 92.6 [85.2 ; 96.9] 0.20 0.20 0.45 0.73 
Sp % [95% CI] All sera n=206 90.3 [86.2 ; 94.3] 91.3 [87.4 ; 95.1] 81.5 [76.3 ; 86.9] <0.01 0.8 0.02 0.02 
 
Group 1 n=192 91.7 [86.8 ; 95.2] 92.7 [88.1 ; 96.0] 81.8 [75.6 ; 87.0] <0.01 0.79 <0.01 <0.01 
 
Group 2 n=14 71.4 [41.9 ; 91.6] 71.4 [41.9 ; 91.6] 78.6 [49.2 ; 95.3] 0.87 NA 0.65 0.71 
Youden’s 
indexǁ   All sera n= 436 
0.873 0.830 0.676 
    
DOR 296 [122 ; 715] 116 [59 ; 228] 27 [16 ; 45]  
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B   p-value* McNemar 
  Bordier Bio-Rad IPD  Bordier/ Bio-Rad 
Bordier/ 
IPD 
Bio-Rad/ 
IPD 
Se % [95% CI] All sera n=220 97.7 [95.8 ; 99.7] 93.2 [89.8 ; 96.5] 89.1 [85.0 ; 93.2] <0.01 0.03 <0.01 0.14 
 
Group 3 n=23 95.6 [78.0 ; 99.9] 95.6 [78.0 ; 99.9] 91.3 [72.0 ; 98.9] 0.16 NA 0.56 0.56 
 
Group 4 n=72 98.6 [92.5 ; 99.9] 95.8 [88.3 ; 99.1] 86.1 [75.9 ; 93.1] <0.01 0.5 0.01 0.08 
 
Group 5 n=34 100 [90.0 ; 100] 91.2 [76.3 ; 98.1] 85.2 [68.9 ; 95.1] <0.01 NA NA 0.69 
 
Group 6 n=91 96.7 [90.7 ; 99.3] 91.2 [83.4 ; 96.1] 92.3 [84.8 ; 96.9] 0.25 0.18 0.34  0.76 
Sp % [95% CI] All sera n=59 71.2 [59.6 ; 82.7] 76.3 [65.4 ; 87.1] 84.7 [75.6 ; 93.9] 0.14 0.80 0.10 0.36 
 
Group 1 n=52 75.0 [61.0 ; 86.0] 78.9 [65.3 ; 88.9] 86.5 [74.2 ; 94.4] 0.28 0.79 0.21 0.45 
 
Group 2 n=7 42.9 [9.9 ; 81.6] 57.1 [18.4 ; 90.1] 71.4 [29.0 ; 96.3] 0.37 NA 0.50 0.56 
Youden’s 
indexǁ   All sera n= 279 
0.689 0.695 0.738 
    
DOR 106 [37 ; 303] 44 [20 ; 98] 45 [20 ; 103]  
 419 
 420 
Se: Sensitivity Sp: specificity 421 
*Cochran Q test 422 
†Equivocal results were considered positive 423 
¥McNemar post-hoc tests showed no significant difference  424 
ǁYouden’s index = sensitivity + specificity – 1 425 
NA = not applicable 426 
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 428 
Figure Legends 429 
Figure 1.Receiver operating characteristic (ROC) curves ofPlatelia Aspergillus IgG (Bio-Rad), 430 
ELISA Classic Aspergillus fumigatus IgG (Virion\Serion) and ELISA Aspergillus fumigatus IgG 431 
(Bordier Affinity Products) assays. 432 
Blue curve Platelia Aspergillus IgG (Bio-Rad) 433 
Green curve. ELISA Classic Aspergillus fumigatus IgG (Virion\Serion) 434 
Red curve ELISA Aspergillus fumigatus IgG (Bordier Affinity Products) 435 
 436 
 437 
Figure 2. Quantitative results and distribution of antibodies obtained with three anti-438 
Aspergillus IgG enzyme immunoassays for the diagnosis of chronic pulmonary 439 
aspergillosis and allergic bronchopulmonary aspergillosis.  440 
* Indicates the number of values higher than 200 AU/ml for the Bio-Rad and Virion\Serion assays 441 
The Y scale is logarithmic  442 
dotted line: positive and negative cut-offs 443 
R package beeswarm was used to perform the graph. 444 
Blue square. Platelia Aspergillus IgG (Bio-Rad) 445 
Green triangle. ELISA Classic Aspergillus fumigatus IgG (Virion\Serion) 446 
Red circles. ELISA Aspergillus fumigatus IgG (Bordier Affinity Products) 447 
Controls : groups 1 and 2  448 
Cases : Patients with chronic or allergic aspergillosis (groups 3 to 6) 449 
 450 


